Search Ontology:
ChEBI
navitoclax
- Term ID
- CHEBI:131174
- Synonyms
-
- 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide
- A-855071.0
- ABT 263
- ABT-263
- ABT263
- navitoclax
- navitoclaxum
- Definition
- A N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of 4-{4-[(4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro[biphenyl]-2-yl)methyl]piperazin-1-yl}benzoic acid with the amino group of 4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide. It is a BH3-mimetic drug which targets the anti-apoptotic B-cell lymphoma-2 (BCL-2) family proteins, including BCL-2, BCL-xL, and BCL-w, and induces apoptosis in cancer cells. Currently under clinical investigation as treatment for solid tumors and hematologic malignancies.
- References
-
- CAS:923564-51-6
- Chemspider:21864722
- DrugBank:DB12340
- KEGG:D09935
- LINCS:LSM-42776
- LINCS:LSM-4738
- PDBeChem:1XJ
- PMCID:PMC6011937
- PMID:18085673
- PMID:23291630
- PMID:26575826
- PMID:26958630
- PMID:28713162
- PMID:28947240
- PMID:29156797
- PMID:29237758
- PMID:29580266
- PMID:29753379
- PMID:29913235
- PMID:30224339
- PMID:30614795
- PMID:30721730
- PMID:30919222
- PMID:31276572
- PMID:31367332
- PMID:31399555
- PMID:31459977
- PMID:32247610
- PMID:32337074
- PMID:32446890
- PMID:32509782
- PMID:32611834
- PMID:32652830
- PMID:32675749
- PMID:32687646
- Wikipedia:Navitoclax
- Ontology
- ChEBI ( EBI )
- is a type of
- has_role
-
Show All 9 Terms
Show first 5 Terms
Phenotype
Phenotype resulting from navitoclax
Phenotype where environments contain navitoclax
Phenotype modified by environments containing navitoclax
Human Disease Model